Zoekresultaten - 3 results
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
the following six months. The trial is registered on ClinicalTrials.gov (NCT04527614). FINDINGS: All included residents (n = 85) and staff members (n = 88) were SARS-CoV-2 infection naïve at third dose ...
Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Maes; Alexander Schauwvlieghe; Laurens Liesenborghs; Ann Belmans; Peter Verhamme; Geert Meyfroidt; DAWn-plasma investigators Source: Eur Respir J (2021) Abstract: BACKGROUND: Several randomised clinical ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
n-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of ...